March 23, 2020
Asahi Kasei Pharma has obtained exclusive worldwide rights to develop, manufacture, and market SBI Biotech’s investigational autoimmune disease therapy SBI-3150, the two partners said on March 19. Under the terms of the deal, SBI will receive from Asahi Kasei an...read more